help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2007-1353
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by López, F. J.
Right arrow Articles by Miner, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by López, F. J.
Right arrow Articles by Miner, J. N.
Endocrinology Vol. 149, No. 5 2080-2089
Copyright © 2008 by The Endocrine Society

LGD-5552, an Antiinflammatory Glucocorticoid Receptor Ligand with Reduced Side Effects, in Vivo

Francisco J. López, Robert J. Ardecky, Bruce Bebo, Khalid Benbatoul, Louise De Grandpre, Sha Liu, Mark D. Leibowitz, Keith Marschke, Jon Rosen, Deepa Rungta, Humberto O. Viveros, Wan-Ching Yen, Lin Zhi, Andrés Negro-Vilar and Jeffrey N. Miner

Discovery Research, Ligand Pharmaceuticals, San Diego, California 92121

Address all correspondence and requests for reprints to: Jeffrey N. Miner, Ardea Biosciences, 4939 Directors Place, San Diego, California 92121. E-mail: jminer{at}ardeabio.com.

Treatment of inflammation is often accomplished through the use of glucocorticoids. However, their use is limited by side effects. We have examined the activity of a novel glucocorticoid receptor ligand that binds the receptor efficiently and strongly represses inflammatory gene expression. This compound has potent antiinflammatory activity in vivo and represses the transcription of the inflammatory cytokine monocyte chemoattractant protein-1 and induces the antiinflammatory cytokine IL-10. The compound demonstrates differential gene regulation, compared with commonly prescribed glucocorticoids, effectively inducing some genes and repressing others in a manner different from the glucocorticoid prednisolone. The separation between the antiinflammatory effects of LGD-5552 and the side effects commonly associated with glucocorticoid treatment suggest that this molecule differs significantly from prednisolone and other steroids and may provide a safer therapeutic window for inflammatory conditions now commonly treated with steroidal glucocorticoids.




This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
L. C. Hofbauer and M. Rauner
Minireview: Live and Let Die: Molecular Effects of Glucocorticoids on Bone Cells
Mol. Endocrinol., October 1, 2009; 23(10): 1525 - 1531.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
K. De Bosscher and G. Haegeman
Minireview: Latest Perspectives on Antiinflammatory Actions of Glucocorticoids
Mol. Endocrinol., March 1, 2009; 23(3): 281 - 291.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society